4basebio (XTER:88Q) Accounts Receivable : €0.07 Mil (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is 4basebio Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. 4basebio's accounts receivables for the quarter that ended in Jun. 2023 was €0.07 Mil.

Accounts receivable can be measured by Days Sales Outstanding. 4basebio's Days Sales Outstanding for the quarter that ended in Jun. 2023 was 46.12.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. 4basebio's Net-Net Working Capital per share for the quarter that ended in Jun. 2023 was €-0.42.

4basebio Accounts Receivable Historical Data

The historical data trend for 4basebio's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Accounts Receivable Chart

4basebio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Accounts Receivable

0.09

0.04

0.05

0.06

4basebio Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Accounts Receivable	Get a 7-Day Free Trial			0.14	0.05	0.10	0.06	0.07

4basebio Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

4basebio Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

4basebio's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.07	/	0.277	*	91
=	46.12

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), 4basebio's accounts receivable are only considered to be worth 75% of book value:

4basebio's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(4.147	+	0.75 * 0.07	+	0.5 * 0.232	-	9.492
-	0	-	0)	/	12.3195
=	-0.42

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

4basebio Accounts Receivable Related Terms

Thank you for viewing the detailed overview of 4basebio's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

4basebio (XTER:88Q) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (XTER:88Q) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

4BB:UK

Address

25 Norman Way, Over, Cambridge, GBR, CB24 5QE

Website

https://www.4basebio.com

4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (XTER:88Q) Headlines

No Headlines